iCAD Inc

The global AI in oncology market, valued at US$1.92 billion in 2023, is projected to grow at a CAGR of 29.4%, reaching US$11.52 billion by 2030. Growth drivers include increased healthcare spending, adoption of advanced healthcare infrastructure, rising cancer prevalence, and AI's role in early detection and prevention. Key segments include drug discovery and pharmaceutical/biotech companies, with significant investments and partnerships enhancing treatment efficacy and patient outcomes.

iCad's ProFound Detection version 4.0, cleared by FDA for digital breast tomosynthesis, uses AI to improve cancer detection and specificity, reducing false positives and enhancing identification of aggressive cancers, particularly in dense tissue.

iCAD's ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) received FDA clearance, offering a 6.3% improved AUC and 22% overall detection improvement in aggressive cancers, with options for prior exam integration and cloud-based deployment.